Deals Shaping the Medical Industry (6/06)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
Oakland, CA-based e.l.f. Beauty is significantly increasing its full fiscal year 2023 sales estimate, predicting 38%-39% growth after third quarter sales soared 49% to reach $146.5m. CEO Tarang Amin discusses the white space opportunities contributing to a bullish outlook even beyond the fiscal year.
The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.
The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.